Pediatric Cancer Survivors Experience Premature Aging
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Pediatric Cancer
FDA Approves Additional Dosing Schedule for Rylaze
The new dosing option was approved based on data from a phase 2/3 trial.
Neuroophthalmological Late Effects Common in Pediatric/Adolescent Medulloblastoma
Children and adolescents with medulloblastoma frequently suffer from neuroophthalmological sequelae, a single-center study suggests.
Data Show Similar Patterns of Relapse in Standard- and High-Risk Medulloblastoma
Patterns of relapse are similar in patients with standard-risk and high-risk medulloblastoma, a review suggests.
Tovorafenib Elicits Responses in Young Patients With BRAF-Altered Low-Grade Glioma
Tovorafenib produced responses in young patients with progressive or recurrent BRAF-altered low-grade glioma in a phase 2 trial.
Adcetris Approved for Pediatric Patients With High-Risk Classical Hodgkin Lymphoma
The approval was based on data from the open-label phase 3 AHOD1331 trial.
SAFER Ukraine: A Global Effort to Evacuate Children With Hematologic Cancers From Ukraine
The SAFER program is helping Ukrainian children with cancers and other blood disorders to continue their therapy in Ukraine or at centers in Europe and North America.
Chronic Conditions More Likely Among Survivors of Pediatric Wilms Tumor
Survivors of Wilms tumor are more likely than the general population to experience chronic health conditions, a study suggests.
Substituting Brentuximab Vedotin for Bleomycin Improves EFS in Pediatric Hodgkin Lymphoma
Brentuximab vedotin improved event-free survival but not overall survival.
Treatment Changes May Have Reduced Rates of Invasive Breast Cancer in Childhood Cancer Survivors
The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
- Loading...
Loading...
Next post in Pediatric Cancer
Loading... 
Loading...